Q3 2022 13F Holders as of 9/30/2022
-
Type / Class
-
Equity / Common Stock, par value $0.001 par value per share
-
Shares outstanding
-
73.8M
-
Number of holders
-
128
-
Total 13F shares, excl. options
-
25.7M
-
Shares change
-
+1.91M
-
Total reported value, excl. options
-
$953M
-
Value change
-
+$76.7M
-
Put/Call ratio
-
2.02
-
Number of buys
-
74
-
Number of sells
-
-42
-
Price
-
$37.02
Significant Holders of RELMADA THERAPEUTICS, INC. - Common Stock, par value $0.001 par value per share (RLMD) as of Q3 2022
177 filings reported holding RLMD - RELMADA THERAPEUTICS, INC. - Common Stock, par value $0.001 par value per share as of Q3 2022.
RELMADA THERAPEUTICS, INC. - Common Stock, par value $0.001 par value per share (RLMD) has 128 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 25.7M shares
of 73.8M outstanding shares and own 34.87% of the company stock.
Largest 10 shareholders include RTW INVESTMENTS, LP (2.64M shares), PERCEPTIVE ADVISORS LLC (2.38M shares), BlackRock Inc. (2.15M shares), BVF INC/IL (2.08M shares), RA CAPITAL MANAGEMENT, L.P. (2M shares), VR Adviser, LLC (1.52M shares), VANGUARD GROUP INC (1.44M shares), CITADEL ADVISORS LLC (931K shares), Point72 Asset Management, L.P. (837K shares), and Vivo Capital, LLC (713K shares).
This table shows the top 128 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.